NYSE: NVRONevro Corp Stock
$5.80+0.01 (+0.17%)
Updated Mar 14, 2025
NVRO Price
$5.80
Fair Value Price
N/A
Market Cap
$219.70M
52 Week Low
$3.17
52 Week High
$14.70
P/E
-1.9x
P/B
0.95x
P/S
0.34x
PEG
N/A
Dividend Yield
N/A
Revenue
$408.52M
Earnings
-$113.44M
Gross Margin
66%
Operating Margin
-20.92%
Profit Margin
-27.8%
Debt to Equity
1.4
Operating Cash Flow
-$19M
Beta
1.45
Next Earnings
May 5, 2025
Ex-Dividend
N/A
Next Dividend
N/A
NVRO Overview
Nevro Corp. is a medical device company developing spinal cord stimulation systems. Senza, Senza II, and Senza Omnia are evidence-based neuromodulation platforms for the treatment of chronic pain. It also offers 10 kHz Therapy, a neuromodulation solution for treating chronic pain. Nevro was incorporated in 2006 and is headquartered in Redwood City, CA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine NVRO's potential to beat the market
- NVRO doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Be the first to know about important NVRO news, forecast changes, insider trades & much more!
NVRO News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how NVRO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
NVRO is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
NVRO is good value based on its book value relative to its share price (0.95x), compared to the US Medical Devices industry average (3.94x)
P/B vs Industry Valuation
NVRO is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more NVRO due diligence checks available for Premium users.
Valuation
NVRO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.9x
Industry
41.08x
Market
3,446.61x
NVRO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.95x
Industry
3.94x
NVRO is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
NVRO's financial health
Profit margin
Revenue
$105.5M
Net Income
-$53.1M
Profit Margin
-50.3%
NVRO's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
NVRO's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$553.8M
Liabilities
$322.8M
Debt to equity
1.4
NVRO's short-term assets ($476.00M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NVRO's short-term assets ($476.00M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NVRO's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
NVRO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$18.6M
Investing
$5.3M
Financing
$632.0k
NVRO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
NVRO vs Medical Device Stocks
Nevro Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.